PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12481822

Aerosol medications.

Eumorfia Kondili·Dimitris Georgopoulos
View original source ↗Export metadata ↓

Abstract

Aerosol medications are used commonly in mechanically ventilated patients. Several classes of drugs with different properties and indications may be given by inhalation. In all cases, inhaled therapy's main advantage over the systemic route is that, for a given therapeutic response, the drug dose is several-fold lower, whereas systemic absorption is negligible. Because of this, the side effects are minimized greatly. Additionally, for some medications, the systemic route either causes nonacceptable side effects or results in considerably inferior therapeutic response, rendering the inhaled route the method of choice of drug administration. Bronchodilators, vasoactive drugs, surfactant, antibiotics, and helium are some agents that can be inhaled during mechanical ventilation.

Explore related subjects

Administration, InhalationAerosolsAirway ResistanceHumansNebulizers and VaporizersPharmaceutical PreparationsRespiration, ArtificialJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Eumorfia Kondili, Dimitris Georgopoulos. 2002. Aerosol medications.. https://doi.org/10.1016/s1078-5337(02)00011-4

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗
PubMed2007

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗